Skip to main content
. 2015 May 12;6(24):20474–20484. doi: 10.18632/oncotarget.4105

Figure 5. ICRF187 inhibits CRPC growth of human prostate cancer xenografts.

Figure 5

(A) CRPC LNCaP xenografts were treated with vehicle, 10mg/kg ENZ, 50mg/kg ICRF187 or 5mg/kg ENZ plus 25mg/kg ICRF187 (n = 7/group). Tumor volume and serum PSA levels were measured weekly. (B) Mice bearing ENZ-resistant MR49F tumors were randomly divided into three groups (n = 9/group) and treated with 10mg/kg ENZ, 10mg/kg ENZ plus 25mg/kg ICRF187, or 10mg/kg ENZ plus 50mg/kg ICRF187. Tumor volume and serum PSA levels were measured. (C) CRPC 22RV1 and (D) PC3 xenografts were treated with control or 50mg/kg or ICRF187. Tumor volumes were measured. Statistical analyses were performed by one-way ANOVA followed by student t-test with P < 0.05 as * and P < 0.01 as **.